Tweet We can see the people making CD20 depleting antibodies and they want to position themselves versus the other antibodies and the other drugs. If you are a fantastic inhibitor of the immune response, it is likely that you will increase the risk of infection. Now the companies do their upmost to play down infection…
It’s been a minute
I’ve been missing from these pages and it feels like losing a limb. Words are usually more reliable for me. They don’t normally let me down. I don’t like it. I’ve lost interest in writing about my disease. It’s become boring to me. It never changes. It never gets any better. It barely gets any…
What I’ve learned from starting a new diet to better manage MS symptoms
Now that the holiday season, with all its decadent meals, is over, I wanted to share an update on the diet I mentioned in a column last September. At the time, I was still in the elimination phase of a FODMAP diet (which stands for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols). Since then, I’ve gradually…
Heavy Weight On Shoulders
Happy Friday Eve, y’all! I hope you are doing well, and the week has treated you well. It has been a while since my last post, and I had promised myself I would write more, but too many things have gotten in the way. When I do write something, I am sharing it with others,…
ACTRIMS 2026: GA Depot shot keeps disability stable for most PPMS patients
A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma at the Americas Committee for Treatment and…
ACTRIMS 2026: Scientists, at ‘crossroads,’ look at MS research
Researchers and clinicians are gathering in San Diego and online for the 11th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, a three-day meeting focused on multiple sclerosis (MS) research and care. ACTRIMS 2026, being held Feb. 5-7 at the Marriott Marquis San Diego Marina, features more than 400 poster presentations,…
Febrer, el Mes de la Mobilitat Assistida
Febrer és el Mes de la Mobilitat Assistida, una iniciativa que posa el focus en les diferents solucions existents per facilitar el desplaçament de persones amb dificultats de mobilitat i promoure una major autonomia en el dia a dia. L’objectiu és acostar a la ciutadania informació pràctica sobre els recursos de suport a la mobilitat,…
EBV the target
Tweet Meloni C, Marnetto F, Fagnani C, Benincasa L, Galano D, Trivedi P, Valentino P, Martire S, Di Sapio A, Bertolotto A, Repice AM, Ballerini C, Mancosu C, Frau J, Cocco E, Veroni C. EBV Dysregulation Is Associated With Immune Imbalance in Multiple Sclerosis: Evidence From Integrated Viral and Host Analyses. Neurol Neuroimmunol Neuroinflamm. 2026…
New study connects immune cell behavior to Mavenclad response in MS
A new study suggests that how certain immune cells respond to Mavenclad (cladribine) may help explain why the treatment works well for some people with multiple sclerosis (MS), but less so for others. The researchers found that regulatory T-cells, or Tregs — immune cells that normally help keep inflammation in check — are relatively resistant…
Partners to provide Mayzent access for SPMS patients in Canada
Teva Canada and Novartis Canada formed a partnership to ensure continued access to Mayzent (siponimod) for people in Canada living with active secondary progressive multiple sclerosis (SPMS). Teva Canada will take over the promotion, distribution, and commercialization of the oral MS therapy in Canada. The companies say the collaboration is intended to support patients and…